10-Q: Goldenwell Biotech Reports Weak Q2 2024 Results Amidst Going Concern Concerns

Goldenwell Biotech's Q2 2024 results reveal minimal revenue, increased losses, and substantial doubt about the company's ability to continue as a going concern.

Summary

• Goldenwell Biotech reported its financial results for the quarter ended June 30, 2024.
• The company's revenue for the quarter was $139, a decrease from $276 in the same period last year.
• The net loss for the quarter was $49,920, compared to a net loss of $27,084 in the prior year's quarter.
• For the six months ended June 30, 2024, revenue was $297, significantly lower than the $1,698 reported in the first half of 2023.
• The net loss for the six-month period was $80,897, compared to $60,690 in the same period last year.
• The company's financial statements have been prepared on a going concern basis, but there is substantial doubt about its ability to continue as such.
• As of June 30, 2024, Goldenwell Biotech had cash of $25,720 and a working capital balance of $3,827.
• The company plans to increase sales and is seeking additional funding through debt or equity offerings.
• Management acknowledges that failure to secure additional financing will lead to business failure.

Sentiment

Score: 2

Explanation: The document paints a bleak picture of the company's financial health, with declining revenue, increasing losses, and a going concern warning. The company's reliance on future funding and the admission that the business will fail without it further contribute to the negative sentiment.

Positives

• The company reports having sufficient cash on hand ($25,720) to fund ongoing operational expenses through December 31, 2024.

Negatives

• Revenue has significantly decreased compared to the previous year.
• Net losses have increased compared to the previous year.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a significant accumulated net loss of $1,308,578 since inception.
• The company's working capital is very low at $3,827.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on raising capital.
• Failure to obtain additional financing will result in business failure.
• Existing shareholders will experience dilution if the company is successful in completing an equity financing.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.
• The company needs approximately $5,000,000 to construct manufacturing facilities and train its workforce.

Future Outlook

The company plans to increase sales of its products and is seeking additional funding through debt or equity offerings to finance its operations. Management believes it can satisfy its cash requirements through the fiscal year end of December 31, 2024, from its cash of $25,720 as of June 30, 2024.

Management Comments

• The ability of the Company to continue as a going concern is dependent on raising capital to fund our business plan and ultimately to attain profitable operations.
• There is no guarantee that the Company will be able to raise any capital through this or any other offerings.
• In the absence of such financing, our business will fail.

Industry Context

The nutraceutical and dietary supplements industry is highly competitive, and Goldenwell Biotech faces challenges in establishing a market presence and achieving profitability. The company's financial struggles highlight the difficulties faced by early-stage companies in this sector, particularly in securing funding and scaling operations.

Comparison to Industry Standards

• Given the limited information, a direct comparison to industry standards is difficult.
• However, many small biotech companies rely on venture capital or angel investors for early-stage funding, a route Goldenwell Biotech appears to be pursuing.
• Compared to established players in the nutraceutical industry, Goldenwell Biotech's revenue is negligible, and its losses are significant relative to its size.
• Companies like Herbalife Nutrition and Amway have well-established distribution networks and brand recognition, which Goldenwell Biotech lacks.

Legal Proceedings

• The Company is not currently subject to any legal proceedings.

Related Party Transactions

• On June 7, 2021, the Company purchased inventory of $103,125 from Australian Trefoil Heath Technology, which is owned by Li, Yang, the Treasurer of the Company.
• On December 21, 2022, the Company borrowed a long-term loan from Shuang Liu, the Chief Executive Officer of the Company.
• On March 16, 2023, the Company borrowed a long-term loan from Shuang Liu.
• On July 17, 2023, the Company borrowed a long-term loan from Shuang Liu.
• On November 1 and November 14, 2023, the Company borrowed a long-term loan from Shuang Liu.

Stakeholder Impact

• Shareholders face significant risk of dilution if the company raises capital through equity offerings.
• Employees' jobs are at risk if the company fails to secure additional funding.
• Customers may be affected if the company is unable to continue operations and provide its products.
• Creditors face the risk of non-payment if the company fails.

Next Steps

• The company plans to increase the sales of its products.
• The company plans to raise additional funds through debt or equity offerings.
• The company must construct manufacturing facilities, which includes locating a site, installing a workshop and setting up equipment.
• The company's workforce will need to be trained.

Key Dates

Keywords

financial results, biotech, going concern, net loss, revenue, Goldenwell Biotech, 10-Q